← Leaderboards
Dorcas J Lynn
Ohio State University
$346
Attributed
$346
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $346 · FY2005–08$500$375$250$125$0
'05
'06
'07
'08
Funding mix
By agency
NIH$346 · 2
AHRQ$0 · 4
CDC$0 · 1
By mechanism
M01$346 · 2
P20$0 · 1
R01$0 · 1
R13$0 · 2
U01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Kottil Rammohan$924,380
- Lisa Michelle Christian$6,976,440
- Jacob Yount$9,023,802
- Charles G Orosz$3,562,189
- Jerry Mendell$11,877,761
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectChronic Obstructive Pulmonary DiseaseMeeting /Conference /SymposiumHealth Care QualityInformation DisseminationIatrogenic DiseaseBehavioral /Social Science Research TagHeart FailureHealth Science ResearchExtended CareAgingPatient Care ManagementInformation SystemsHuman DataDisease /Disorder Prevention /ControlInterferon BetaHuman Therapy EvaluationImmunopathology ChemotherapyHealth Services Research TagHealth Care Service EvaluationDrug Screening /EvaluationDrug Administration Rate /DurationHealth Care Cost /Financing
Grant awards (11)
CLINICAL TRIAL: REBIF (IFN BETA-1A) AND BETASERON (IFN BETA-1B) IN IFN-NAIVE MS$346
M01 · FY2008 · RR · contact PI
Improving Influeza Immunization In Long Term Care Staff$0
U01 · FY2005 · IP
Improving Influeza Immunization In Long Term Care Staff$0
U01 · FY2004 · IP
Center for Patient Safety at the End of Life$0
P20 · FY2003 · HS
Center for Patient Safety at the End of Life$0
P20 · FY2002 · HS
EPISTEMOLOGY AND ETHICS OF QUALITY IMPROVEMENT$0
R13 · FY2001 · HS
Center for Patient Safety at the End of Life$0
P20 · FY2001 · HS
IMPROVEMENTS &INNOVATIONS IN END OF LIFE CARE$0
R13 · FY2001 · HS
TWO DOSES OF BETASERON IN PATIENTS WITH SECONDARY PROGR$0
M01 · FY2000 · RR
A DETAILED PROFILE OF THE END-OF-LIFE CARE IN MEDICARE$0
R01 · FY2000 · HS
TWO DOSES OF BETASERON IN PATIENTS WITH SECONDARY PROGR$0
M01 · FY2000 · RR